Emerging drugs for Waldenström's macroglobulinemia

Bibliography

• Owen RG, Treon SP, Al-Katib A, Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;16(2):110-15
   Google Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23(7):1564-77
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zervas K, Repoussis P, Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 2009;9(1):50-2
   PubMedGoogle Scholar
• Silvestri F, Barillari G, Fanin R, Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies. Blood 1996;88(3):1125-6
   PubMed Web of Science ®Google Scholar
• Mussini C, Ghini M, Mascia MT, Monoclonal gammopathies and hepatitis C virus infection. Blood 1995;85(4):1144-5
   PubMed Web of Science ®Google Scholar
• Andreone P, Gramenzi A, Cursaro C, Bernardi M. Hepatitis C virus infection and lymphoproliferative disorders. Blood 1995;86(9):3610-11
   PubMed Web of Science ®Google Scholar
• Izumi T, Sasaki R, Shimizu R, Hepatitis C virus infection in Waldenstrom's macroglobulinemia. Am J Hematol 1996;52(3):238-9
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Smedby KE, Hjalgrim H, Hepatitis C infection and risk of malignant lymphoma. Int J cancer 2008;122(8):1885-90
   PubMed Web of Science ®Google Scholar
• Santini GF, Crovatto M, Modolo ML, Waldenstrom macroglobulinemia: a role of HCV infection? Blood 1993;82(9):2932
   PubMed Web of Science ®Google Scholar
• Custodi P, Cerutti A, Cassani P, Familial occurrence of IgMk gammapathy: no involvement of HCV infection. Haematologica 1995;80(5):484-5
   PubMedGoogle Scholar
• Leleu X, O'Connor K, Ho AW, Hepatitis C viral infection is not associated with Waldenstrom's macroglobulinemia. Am J Hematol 2007;82(1):83-4
   PubMed Web of Science ®Google Scholar
• Mikala G, Xie J, Berencsi G, Human herpesvirus 8 in hematologic diseases. Pathol Oncol Res 1999;5(1):73-9
   PubMedGoogle Scholar
• Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109(12):5096-103
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Aggarwal A, Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17(3):488-94
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Montoto S, Torrequebrada A, Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001;115(3):575-82
   PubMed Web of Science ®Google Scholar
• Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom's macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004:257-82
   PubMedGoogle Scholar
• Kyle RA, Treon SP, Alexanian R, Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30(2):116-20
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114(12):2375-85
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000;18(1):214-26
   PubMed Web of Science ®Google Scholar
• Siami GA, Siami FS. Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenstrom's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis. Ther Apher 1999;3(1):8-19
   PubMedGoogle Scholar
• Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher 2002;6(1):45-52
   PubMedGoogle Scholar
• Stone MJ. Waldenstrom's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 2009;9(1):97-9
   PubMedGoogle Scholar
• Nobile-Orazio E, Marmiroli P, Baldini L, Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987;37(9):1506-14
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Francomano E, Daverio R, Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol 1989;26(4):543-50
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E. IgM paraproteinaemic neuropathies. Curr Opin Neurol 2004;17(5):599-605
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27(1):120-6
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23(1):153-61
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25(22):3344-9
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Richardson PG, Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):309-12
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Leleu X, Sacco A, Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008;111(9):4752-63
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Leleu X, Role of proteasome inhibition in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9(1):94-6
   PubMedGoogle Scholar
• Leleu X, Jia X, Runnels J, The Akt pathway regulates survival and homing in Waldenstrom Macroglobulinemia. Blood 2007;110(13):4417-26
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Husu EN, Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010;115(3):559-69
   PubMed Web of Science ®Google Scholar
• Ho AW, Hatjiharissi E, Ciccarelli BT, CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008;112(12):4683-9
   PubMed Web of Science ®Google Scholar
• Santos DD, Hatjiharissi E, Tournilhac O, CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006;6(6):478-83
   PubMedGoogle Scholar
• Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27(9):1492-501
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002;128(11):603-9
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(27):4473-9
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting Abstracts 2009;114(22):405
   Google Scholar
• Leleu X, Xu L, Jia X, Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2009;113(3):626-34
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Aujay M, Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010;115(20):4051-60
   PubMed Web of Science ®Google Scholar
• Hideshima T, Ikeda H, Chauhan D, Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114(5):1046-52
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90(12):1655-8
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13(11):3320-5
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(12):1570-5
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1422-8
   PubMed Web of Science ®Google Scholar
• Agathocleous A, Rule S, Johnson P, Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia. ASH Annual Meeting Abstracts 2007;110(11):2559
   Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27(23):3830-5
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos MA. Thalidomide in the treatment of multiple myeloma. Best Pract Res Clin Haematol 2007;20(4):681-99
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA, Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001;19(16):3596-601
   PubMed Web of Science ®Google Scholar
• Coleman M, Leonard J, Lyons L, BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma 2002;43(9):1777-82
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tsatalas C, Zomas A, Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003;30(2):265-9
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008;22(7):1343-53
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15(1):355-60
   PubMed Web of Science ®Google Scholar
• Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006;7(4):285-94
   PubMedGoogle Scholar
• Witzig TE, Geyer SM, Ghobrial I, Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23(23):5347-56
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1408-14
   PubMed Web of Science ®Google Scholar
• Campbell RA, Sanchez E, Steinberg J, The mTOR inhibitor RAD001 (everolimus) inhibits myeloma tumor growth in vivo and enhances the anti-MM effects of bortezomib and arsenic trioxide. ASH Annual Meeting Abstracts 2007;110(11):4801
   Google Scholar
• Ghobrial IM, Roccaro A, Hong F, Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
   PubMed Web of Science ®Google Scholar
• Treon SP, Kelliher A, Keele B, Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol 2003;30(2):248-52
   PubMed Web of Science ®Google Scholar
• Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma 2005;5(4):278-81
   PubMedGoogle Scholar
• Tournilhac O, Santos DD, Xu L, Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006;17(8):1275-82
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Boxer M, Kahl B, Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):7523
   Google Scholar
• Konoplev S, Medeiros LJ, Bueso-Ramos CE, Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 2005;124(3):414-20
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Ocio E, Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):187-95
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111(12):5486-95
   PubMed Web of Science ®Google Scholar
• Emmanouilides C. Radioimmunotherapy for Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):258-61
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101(10):4055-62
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Ngo H, Leontovich AA, Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007;67(8):3777-84
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Gertz MA, Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133(2):158-64
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26(2):204-10
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113(18):4163-70
   PubMed Web of Science ®Google Scholar